IN THE SPOTLIGHT ERBB2 Emerges as a New Target for Colorectal Cancer

1 Division of Hematology and Oncology, Beth Israel Deaconess Hospital, Boston, Massachusetts. 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3 Broad Institute of MIT and Harvard, Cambridge, Massachusetts. 4 Departments of Medicine, Brigham & Women’s Hospital and Harvard Medical School, Boston, Massachusetts. Corresponding Author: Adam J. Bass, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115. Phone: 617-632-2477; Fax: 617-5827880; E-mail: [email protected] doi: 10.1158/2159-8290.CD-15-0730 ©2015 American Association for Cancer Research. Summary: ERBB2 mutations and amplifi cations are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefi t from ERBB2-directed therapy. Cancer Discov; 5(8); 799–801. ©2015 AACR.